Investing.com -- Cassava Sciences (NASDAQ:SAVA) stock rose 2.75% on Thursday after the biotechnology company announced that the U.S. Department of Justice (DOJ) has closed its inquiry into allegations ...

Cassava Sciences' stock rose 9% after completing an interim safety analysis for its Alzheimer's drug, Simufilam, but the company's future remains uncertain due to ongoing legal and scientific scrutiny ...

Cassava Sciences (NASDAQ:SAVA) shares advanced 2.75% on Thursday after the biotech firm disclosed that the U.S. Department of Justice has formally closed its investigation into allegations of research ...

Shares of biotech company Cassava Sciences Inc. plummeted on Friday after a federal grand jury indicted a onetime science advisor to Cassava and charged him with falsifying data to obtain millions of ...

The MarketWatch News Department was not involved in the creation of this content. DELRAY BEACH, Fla., July 23, 2025 /PRNewswire/ -- According to MarketsandMarkets(TM), The modified cassava starch ...

Cassava Sciences' Alzheimer's drug simufilam failed its Phase 3 trial, causing the stock to plummet ~90% and trade near book value. The company's decision to discontinue other simufilam trials signals ...

Investors with a lot of money to spend have taken a bearish stance on Cassava Sciences (NASDAQ:SAVA). And retail traders should know. We noticed this today when the trades showed up on publicly ...

An independent DSMB reviewed interim safety data for simufilam and recommended the trials proceed without modifications. Two ongoing trials with over 1,900 Alzheimer’s patients; top-line results from ...

Cassava, also known as yuca or manioc, was once known mostly in Caribbean, African, and South American cuisines—but has grown in popularity, popping up as an ingredient in countless gluten-free and ...

Cassava, also known as yuca or manioc, was once known mostly in Caribbean, African, and South American cuisines — but has grown in popularity, popping up as an ingredient in countless gluten-free and ...